Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H14N4O |
Molecular Weight | 266.2979 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C2NC(=O)C3=CC=CN=C3N(C4CC4)C2=NC=C1
InChI
InChIKey=NQDJXKOVJZTUJA-UHFFFAOYSA-N
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
Molecular Formula | C15H14N4O |
Molecular Weight | 266.2979 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00238Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Sources: http://www.drugbank.ca/drugs/DB00238
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. Nevirapine is used for use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22514580
Curator's Comment: Nevirapine (NVP) crosses well the BBB
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL614530 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26086472 |
239.0 µM [EC50] | ||
Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25240095 |
0.31 nM [EC50] | ||
Target ID: CHEMBL247 Sources: http://www.drugbank.ca/drugs/DB00238 |
250.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Viramune Approved UseVIRAMUNE is an NNRTI indicated for combination antiretroviral treatment of HIV-1 infection Launch Date1995 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2060 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
161000 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
82000 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
96700 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Overdose |
unhealthy, 8-days-old Health Status: unhealthy Age Group: 8-days-old Sex: F Sources: |
Other AEs: Neutropenia, Hyperlactatemia... |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Disc. AE: Rash, Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Stevens-Johnson syndrome (1%) Transaminases increased (1%) ALT increased (1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (1%) Malaise (1%) Pyrexia (1%) Fatigue (1%) Vascular disorders (<1%) |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Disc. AE: Rash, Drug rash with eosinophilia and systemic symptoms... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Drug rash with eosinophilia and systemic symptoms (<1%) Transaminases increased (1%) ALT increased (<1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (<1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (<1%) Malaise (<1%) Pyrexia (<1%) Fatigue (<1%) Vascular disorders (<1%) Musculoskeletal and connective tissue disorders (<1%) |
800 mg 1 times / day multiple, oral Overdose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hepatotoxicity, Reaction skin... AEs leading to discontinuation/dose reduction: Hepatotoxicity (grade 5) Sources: Reaction skin (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperlactatemia | 200 mg single, oral Overdose |
unhealthy, 8-days-old Health Status: unhealthy Age Group: 8-days-old Sex: F Sources: |
|
Neutropenia | mild | 200 mg single, oral Overdose |
unhealthy, 8-days-old Health Status: unhealthy Age Group: 8-days-old Sex: F Sources: |
ALT increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Fatigue | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatitis | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatotoxicity | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Malaise | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Nausea | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Pyrexia | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Stevens-Johnson syndrome | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Transaminases increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Rash | 2% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
AST increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
GGT increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatic enzyme increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatitis acute | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatitis toxic | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Vascular disorders | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatitis | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Transaminases increased | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Rash | 2% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
ALT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
AST increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Drug rash with eosinophilia and systemic symptoms | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Fatigue | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
GGT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatic enzyme increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatitis acute | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatitis toxic | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatotoxicity | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Malaise | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Musculoskeletal and connective tissue disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Nausea | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Pyrexia | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Vascular disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: |
Hepatotoxicity | grade 5 Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Reaction skin | severe Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. | 1999 Aug 20 |
|
Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors. | 1999 Dec |
|
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. | 1999 Dec |
|
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. | 1999 Dec 20 |
|
5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. | 1999 Feb 25 |
|
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. | 1999 Sep 20 |
|
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. | 2000 Aug |
|
Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine. | 2000 Feb 15 |
|
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients. | 2000 Jun 10 |
|
Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. | 2000 May 4 |
|
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. | 2000 Oct 19 |
|
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. | 2001 |
|
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child. | 2001 Apr |
|
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. | 2001 Apr |
|
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. | 2001 Apr |
|
Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. | 2001 Apr 1 |
|
Revised nevirapine insert. | 2001 Feb |
|
Indian company offers cheap anti-AIDS drugs. | 2001 Feb 15 |
|
Nevirapine and postexposure prophylaxis for human immunodeficiency virus. | 2001 Feb 21 |
|
Prevention of nevirapine-associated rash. | 2001 Feb 3 |
|
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. | 2001 Jan |
|
Pharmacokinetic of nevirapine in haemodialysis. | 2001 Jan |
|
Ritonavir-induced carbamazepine toxicity. | 2001 Jan |
|
Need for increased dose of warfarin in HIV patients taking nevirapine. | 2001 Jan 26 |
|
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. | 2001 Jan 5 |
|
Sequence-specific detection of individual DNA strands using engineered nanopores. | 2001 Jul |
|
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. | 2001 Jul |
|
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. | 2001 Jul 6 |
|
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001 Jun |
|
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. | 2001 Jun |
|
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | 2001 Jun 1 |
|
South Africa in crisis on HIV/AIDS treatment. | 2001 Jun 29 |
|
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. | 2001 Mar 1 |
|
Sequencing antiretroviral drugs. | 2001 Mar 30 |
|
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients]. | 2001 Mar 31 |
|
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | 2001 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/nevirapine.html
The recommended dose for Nevirapine is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16752922
The IC50 value for inhibition by nevirapine against immunodeficiency virus type 1 (HIV) nucleoside reverse transcriptase (RT) in removal assay was 3 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:54 GMT 2025
by
admin
on
Mon Mar 31 17:59:54 GMT 2025
|
Record UNII |
99DK7FVK1H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
NEVIRAPINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
NCI_THESAURUS |
C97453
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-ATC |
J05AR05
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-VATC |
QJ05AG01
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
NDF-RT |
N0000175463
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
VIRAMUNE (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
LIVERTOX |
NBK548895
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.2
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-VATC |
QJ05AR07
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
NDF-RT |
N0000009948
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
NDF-RT |
N0000175460
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/STA)
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-ATC |
J05AG01
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
FDA ORPHAN DRUG |
293409
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/ZID)
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-VATC |
QJ05AR05
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
||
|
WHO-ATC |
J05AR07
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09214MIG
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
N0000190118
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | Cytochrome P450 3A Inducers [MoA] | ||
|
DTXSID7031797
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
53654
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
Nevirapine
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
SUB25191
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
1460703
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
63613
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
6815
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
NEVIRAPINE
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL57
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
100000085470
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
99DK7FVK1H
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
D019829
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
m7845
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
641530
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
129618-40-2
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
NEVIRAPINE
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | Description: A white to almost white powder. Solubility: Practically insoluble in water, sparingly to slightly soluble in dichloromethane R, slightly soluble in methanol R. Category: Antiretroviral (Non-Nucleoside Reverse Transcriptase Inhibitor). Storage: Nevirapine should be kept in a well-closed container. Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form. Definition: Nevirapine contains not less than 98.0% and not more than 102.0% of nevirapine (C15H14N4O), calculated with reference to the anhydrous substance. | ||
|
DB00238
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
1904
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
DD-19
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
C29277
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
4463
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
7164
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | |||
|
N0000187064
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY | Cytochrome P450 2B6 Inducers [MoA] | ||
|
99DK7FVK1H
Created by
admin on Mon Mar 31 17:59:54 GMT 2025 , Edited by admin on Mon Mar 31 17:59:54 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
SUBSTANCE->BASIS OF STRENGTH |
|
||
|
TARGET ORGANISM->INHIBITOR |
IC50 values (50% inhibitory
concentration) ranged from 10-100 nM against laboratory and clinical isolates of HIV-1.
IC50
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
This reactive intermediate was catalyzed
primarily by CYP3A and possibly by CYP2D6, CYP2C19,
and CYP2A6
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
Amount NOT SPECIFIED
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
The test is not valid unless the resolution between nevirapine and nevirapine impurity B RS is not less than 5. In the chromatogram obtained with solution (3) the peak due to impurity (B) is eluted at a relative retention of about 0.7 with reference to nevirapine (retention time about 7.6 minutes).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Amount NOT SPECIFIED
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||